SLN Silence Therapeutics Plc
Price (delayed)
$2.61
Market cap
$123.13M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.99
Enterprise value
$1.92M
Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform
Highlights
Silence Therapeutics's quick ratio has surged by 185% YoY and by 15% QoQ
SLN's revenue has soared by 114% from the previous quarter and by 37% YoY
Key stats
What are the main financial stats of SLN
Market
Valuations
Earnings
Shares outstanding
47.18M
Market cap
$123.13M
Enterprise value
$1.92M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
2.79
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.04
Revenue
$43.26M
Gross profit
$31.45M
Operating income
-$63.32M
Net income
-$45.31M
EBIT
-$44.46M
EBITDA
-$43.87M
Free cash flow
-$67.85M
Per share
Balance sheet
Liquidity
EPS
-$0.99
EPS diluted
-$0.99
Free cash flow per share
-$1.47
Book value per share
-$2.84
Revenue per share
$0.94
TBVPS
$4.18
Total assets
$202.64M
Total liabilities
$68.61M
Debt
$117,000
Equity
-$134.02M
Working capital
$170.54M
Debt to equity
0
Current ratio
11.14
Quick ratio
8.82
Net debt/EBITDA
2.76
Margins
Efficiency
Dividend
EBITDA margin
-101.4%
Gross margin
72.7%
Net margin
-104.7%
Operating margin
-146.4%
Return on assets
-20.3%
Return on equity
-64.8%
Return on invested capital
-59.4%
Return on capital employed
-23.9%
Return on sales
-102.8%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
SLN stock price
How has the Silence Therapeutics stock price performed over time
Intraday
-4.74%
1 week
-24.13%
1 month
-41.74%
1 year
-87.82%
YTD
-62.06%
QTD
-7.45%
Financial performance
How have Silence Therapeutics's revenue and profit performed over time
Revenue
$43.26M
Gross profit
$31.45M
Operating income
-$63.32M
Net income
-$45.31M
Gross margin
72.7%
Net margin
-104.7%
SLN's revenue has soared by 114% from the previous quarter and by 37% YoY
Silence Therapeutics's net margin has soared by 71% from the previous quarter and by 39% YoY
The gross profit has soared by 67% YoY
Silence Therapeutics's gross margin has surged by 63% QoQ and by 23% YoY
Growth
What is Silence Therapeutics's growth rate over time
Valuation
What is Silence Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
2.79
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.04
Silence Therapeutics's EPS has increased by 33% YoY
SLN's revenue has soared by 114% from the previous quarter and by 37% YoY
The P/S is 91% lower than the 5-year quarterly average of 29.5 and 90% lower than the last 4 quarters average of 28.2
Efficiency
How efficient is Silence Therapeutics business performance
SLN's return on equity has surged by 88% year-on-year and by 14% since the previous quarter
SLN's ROIC has soared by 70% YoY and by 37% from the previous quarter
Silence Therapeutics's return on sales has surged by 66% QoQ and by 39% YoY
SLN's ROA has soared by 55% YoY and by 44% from the previous quarter
Dividends
What is SLN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for SLN.
Financial health
How did Silence Therapeutics financials performed over time
The total assets is 195% more than the total liabilities
Silence Therapeutics's quick ratio has surged by 185% YoY and by 15% QoQ
Silence Therapeutics's current ratio has soared by 141% YoY and by 20% from the previous quarter
Silence Therapeutics's debt is 100% more than its equity
The debt to equity has soared by 100% year-on-year
Silence Therapeutics's debt has plunged by 66% YoY and by 33% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.